Stockscreener 앱 받기
11.27
0.99%
0.11
전일 마감가:
$11.16
열려 있는:
$11.35
하루 거래량:
595.14K
Relative Volume:
0.64
시가총액:
$881.28M
수익:
$54.55M
순이익/손실:
$-193.57M
주가수익비율:
-3.8997
EPS:
-2.89
순현금흐름:
$-181.86M
1주 성능:
-2.51%
1개월 성능:
-0.97%
6개월 성능:
-53.94%
1년 성능:
-11.47%
1일 변동 폭
$11.18
$11.56
1주일 범위
$11.05
$11.72
52주 변동 폭
$8.18
$29.56
누릭스 테라퓨틱스 Stock (NRIX) Company Profile
명칭
Nurix Therapeutics Inc
전화
(415) 660-5320
주소
1700 OWENS STREET, SUITE 205, SAN FRANCISCO
NRIX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NRIX
Nurix Therapeutics Inc
|
11.27 | 881.28M | 54.55M | -193.57M | -181.86M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.15 | 126.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.61 | 65.06B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
649.67 | 37.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
259.39 | 32.56B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.77 | 26.40B | 3.81B | -644.79M | -669.77M | -6.24 |
누릭스 테라퓨틱스 Stock (NRIX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-17 | 개시 | Leerink Partners | Market Perform |
| 2024-12-10 | 개시 | BTIG Research | Buy |
| 2024-12-06 | 개시 | BMO Capital Markets | Outperform |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-10-11 | 개시 | Jefferies | Buy |
| 2024-09-06 | 재개 | Robert W. Baird | Outperform |
| 2024-07-31 | 개시 | Truist | Buy |
| 2023-06-26 | 재개 | Oppenheimer | Outperform |
| 2023-03-09 | 개시 | Barclays | Overweight |
| 2023-02-28 | 개시 | Oppenheimer | Outperform |
| 2022-10-11 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-05-31 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-02-10 | 개시 | Wells Fargo | Equal Weight |
| 2021-12-29 | 개시 | H.C. Wainwright | Buy |
| 2021-10-14 | 개시 | SVB Leerink | Outperform |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-04-30 | 재개 | Piper Sandler | Overweight |
| 2021-04-30 | 개시 | RBC Capital Mkts | Outperform |
| 2021-04-14 | 개시 | Berenberg | Buy |
| 2020-11-19 | 개시 | Robert W. Baird | Outperform |
| 2020-08-18 | 개시 | JP Morgan | Overweight |
| 2020-08-18 | 개시 | Needham | Buy |
| 2020-08-18 | 개시 | Piper Sandler | Overweight |
| 2020-08-18 | 개시 | Stifel | Buy |
모두보기
누릭스 테라퓨틱스 주식(NRIX)의 최신 뉴스
(NRIX) Trading Signals - news.stocktradersdaily.com
JPMorgan Chase & Co. Reduces Stock Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Receives "Buy" Rating from Needham & Company LLC - MarketBeat
Darwin Global Management Ltd. Takes $3.08 Million Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Price T Rowe Associates Inc. MD Lowers Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix therapeutics’ chief scientific officer sells $38,841 in stock By Investing.com - Investing.com Canada
Nurix therapeutics’ chief scientific officer sells $38,841 in stock - Investing.com
Nurix Therapeutics Executives Sell Shares for Tax Obligations - TradingView
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Purchased by Lord Abbett & CO. LLC - MarketBeat
T. Rowe Price Investment Management Inc. Sells 167,663 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Breaking Down Nurix Therapeutics: 7 Analysts Share Their Views - Benzinga
Nurix Therapeutics Presents Data at the AACR 2025 Annual Meeting Highlighting the Transformative Potential of Its Proprietary DEL-AI Platform Leveraging Machine Learning to Speed the Discovery of Novel Drugs - The Manila Times
Russell Investments Group Ltd. Grows Stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Stock Price Up 6.4%Here's Why - MarketBeat
Nurix Therapeutics reports breakthroughs in cancer drug research - Investing.com Australia
Jump Financial LLC Purchases New Stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics Presents Positive Preclinical Data at the AAC - GuruFocus
Nurix Therapeutics Showcases Promising Preclinical Data for BTK, BRAF, and Aurora A Kinase Degraders at AACR 2025 Annual Meeting - Nasdaq
Nurix Therapeutics Presents Positive Preclinical Data at the AACR 2025 Annual Meeting from Multiple Orally Available, Brain Penetrant Degraders Against Three High Value Oncology Targets - The Manila Times
Revolutionary Brain-Penetrant Cancer Drugs Outperform Competitors: 10,000 Proteins Destroyed Per Hour - Stock Titan
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives $30.44 Average Price Target from Analysts - MarketBeat
Geode Capital Management LLC Acquires 137,087 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Shares Gap DownWhat's Next? - MarketBeat
Affinity Asset Advisors LLC Raises Stock Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Wasatch Advisors LP Lowers Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Fmr LLC Grows Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Sold by Trexquant Investment LP - MarketBeat
(NRIX) Technical Data - news.stocktradersdaily.com
Nurix advances IRAK4 degrader into Phase 1 trials with FDA nod - Investing.com Canada
Nurix Therapeutics: IRAK4 GS-6971 Isn't Only Protein Degrader With Big Potential - Seeking Alpha
Broker Revenue Forecasts For Nurix Therapeutics, Inc. (NASDAQ:NRIX) Are Surging Higher - simplywall.st
Nurix advances IRAK4 degrader into Phase 1 trials with FDA nod By Investing.com - Investing.com South Africa
Nurix Therapeutics (NRIX) Advances Experimental Drug Following FDA Clearance - GuruFocus
Nurix gets FDA clearance to initiate trial for its anti-inflammatory drug candidate - Seeking Alpha
FDA Clears IND for Nurix's (NRIX) IRAK4 Degrader, Phase 1 Trial Set for 2025 | NRIX Stock News - GuruFocus
Nurix Announces FDA Clearance of IND Application for GS-6791/NX-0479a Novel IRAK4 Degrader for Inflammatory Conditions - The Manila Times
Nurix Therapeutics Announces FDA Clearance for GS-6791/NX-0479 IND, Phase 1 Trials Set to Begin in Q2 2025 in Collaboration with Gilead Sciences - Nasdaq
FDA Green Lights Groundbreaking IRAK4 Degrader: $420M Milestone Potential in Inflammatory Disease Fight - Stock Titan
Leerink Partnrs Has Optimistic Outlook of NRIX Q2 Earnings - MarketBeat
Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Tops Revenue Estimates - MSN
NRIX Stock Up as SNY In-Licenses Rights to Autoimmune Diseases Program - MSN
Vanguard Group Inc. Boosts Stock Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Norges Bank Makes New $6.01 Million Investment in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
누릭스 테라퓨틱스 (NRIX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.47%
2.63%
자본화:
|
볼륨(24시간):